These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23987161)

  • 1. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
    Lewandowski J; Sinski M; Symonides B; Korecki J; Rogowski K; Judycki J; Sieczych A; Możeńska O; Gaciong Z
    Urology; 2013 Sep; 82(3):660-5. PubMed ID: 23987161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
    Farshi A; DalirAkbari N; Zomorrodi A; Khalili M; Mahmoudinezhad M
    Urol J; 2021 Apr; 18(3):337-342. PubMed ID: 33840085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
    Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
    Safarinejad MR
    J Herb Pharmacother; 2005; 5(4):1-11. PubMed ID: 16635963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BiVap saline vaporization of the prostate in men with benign prostatic hyperplasia: our clinical experience.
    Karakose A; Aydogdu O; Atesci YZ
    Urology; 2014 Mar; 83(3):570-5. PubMed ID: 24275275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
    BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-year follow-up after transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia; long-term results of a randomized controlled trial.
    Hoekstra RJ; Van Melick HH; Kok ET; Ruud Bosch JL
    BJU Int; 2010 Sep; 106(6):822-6. PubMed ID: 20184573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment.
    Woo HH
    Urology; 2013 Sep; 82(3):665; discussion 665-6. PubMed ID: 23987162
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
    Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
    Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.